- Home
- CSTL vs BALY Comparison
CSTL vs BALY Comparison
Compare CSTL & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | BALY |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | 11700 |
| Industry | Medical Specialities | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 669.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CSTL | BALY |
|---|---|---|
| Price | $21.05 | $14.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $45.50 | $12.40 |
| AVG Volume (30 Days) | ★ 468.8K | 37.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.37 |
| EPS | ★ N/A | N/A |
| Revenue | $344,229,000.00 | ★ $2,436,189,000.00 |
| Revenue This Year | $2.42 | $21.50 |
| Revenue Next Year | $12.69 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $8.46 |
| 52 Week High | $44.28 | $20.74 |
Technical Indicators
Market Signals| Indicator | CSTL | BALY |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 65.63 |
| Support Level | $17.72 | $11.96 |
| Resistance Level | $24.46 | $14.37 |
| Average True Range (ATR) | 1.12 | 0.78 |
| MACD | 0.37 | 0.25 |
| Stochastic Oscillator | 74.65 | 95.58 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.